ViaCyte CEO to present at Cell & Gene Meeting

By The Science Advisory Board staff writers

October 8, 2021 -- ViaCyte will present data on the latest product candidates the company is developing to treat type 1 diabetes at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14 at 10:15 a.m. PST.

Michael Yang, the company's chief executive officer, will discuss ViaCyte's clinical proof of concept indicating that its stem cell-derived islet replacement therapy may potentially produce insulin and regulate blood glucose in patients with type 1 diabetes.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter